A Phase 3, Randomized, Double-mask, Placebo-controlled Study With Open-label Extension to Evaluate the Efficacy and Safety of Linsitinib in Participants With Moderate to Severe Active Thyroid Eye Disease (TED)

The goal of this clinical trial is to evaluate the efficacy, safety, and tolerability of linsitinib in participants with moderate to severe Thyroid Eye Disease (TED).

Start Date04 Aug 2026

Sponsor / Collaborator

Sling Therapeutics, Inc.

NCT06112340

/ RecruitingPhase 2/3

A Multicenter, Extension Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

The overall study objective is to continue to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of linsitinib in subjects who were enrolled in the prior VGN-TED-301 through Week 24. These subjects include VGN-TED-301 Week 24 proptosis non-responders or subjects who relapse during the Follow-Up Period of VGN-TED-301.

Start Date11 Oct 2023

Sponsor / Collaborator

Sling Therapeutics, Inc.

NCT05276063

/ Active, not recruitingPhase 2/3

A Phase 2b, Randomized, Double-Mask, Placebo-Controlled, Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

The overall objective is to study the safety, pharmacokinetics and efficacy of linsitinib (a small molecule IGF-1R inhibitor) administered orally twice daily (BID) vs. placebo, at 24 weeks in the treatment of subjects with active, moderate to severe thyroid eye disease (TED).

Start Date01 Jul 2022

Sponsor / Collaborator

Sling Therapeutics, Inc.

100 Clinical Results associated with Linsitinib

100 Translational Medicine associated with Linsitinib

100 Patents (Medical) associated with Linsitinib

325

Literatures (Medical) associated with Linsitinib

01 Sep 2026·ARCHIVES OF GERONTOLOGY AND GERIATRICS

Identification of MMP14 and FOS as key regulators of vascular smooth muscle cell senescence in diabetic kidney disease: A combined bioinformatics and experimental study

Article

Author: Wang, Bo ; Wang, Shanshan ; Qu, Bo ; He, Yuhua ; Zhou, Li ; Mao, Bing

OBJECTIVE:

Diabetic kidney disease (DKD) is a leading microvascular complication of diabetes in which vascular smooth muscle cell (VSMC) senescence plays a pivotal pathogenic role. This study aimed to identify key genes regulating VSMC senescence in DKD through integrated bioinformatics and machine learning analysis, construct a diagnostic nomogram prediction model, screen candidate therapeutic compounds, and validate findings experimentally.

METHODS:

Transcriptomic profiles for DKD (GSE30122, GSE96804, GSE142025) and a VSMC aging dataset (GSE198983) were retrieved from the GEO repository. Genes showing differential expression were determined using limma, succeeded by weighted gene co-expression network analysis (WGCNA) and functional annotation through Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG). Feature selection employed random forest, least absolute shrinkage and selection operator (LASSO), and support vector machine-recursive feature elimination (SVM-RFE) to isolate pivotal genes and develop diagnostic frameworks. Immune cell composition was analyzed via CIBERSORT, and competing endogenous RNA (ceRNA) plus transcription factor networks were assembled. Drug candidates were forecasted using the Connectivity Map platform. Human aortic smooth muscle cells (HASMCs), employed as a surrogate macrovascular smooth muscle cell model, and human renal artery smooth muscle cells (HRASMCs), employed as a kidney-proximal vascular model for cross-validation, underwent hyperglycemic exposure to recapitulate DKD conditions, with proliferation, programmed cell death, and senescence evaluated through CCK-8 assays, flow cytometry, and senescence-associated β-galactosidase (SA-β-gal) detection. Expression of p16, p21, osteopontin (OPN), and osteocalcin (OC) was quantified by Western blotting. Cell cycle distribution was additionally assessed by propidium iodide (PI)-based flow cytometry to elucidate the mechanism of proliferative suppression.

RESULTS:

A total of 43 candidate genes demonstrated enrichment predominantly in biological aging, cellular senescence, oxidative damage, insulin signaling cascades, and MAPK transduction pathways. MMP14 and FOS emerged consistently as pivotal genes exhibiting potential diagnostic capability. Immune infiltration disclosed marked changes across multiple immune populations, with MMP14 and FOS expression demonstrating associations with various immune cell subsets. The ceRNA architecture computationally predicted MMP14, FOS, NEAT1, and hsa-miR-181a-5p as critical regulatory nodes, with SRF computationally nominated as a shared transcriptional regulator. Five therapeutic candidates (neratinib, linsitinib, amlodipine, forskolin, piceatannol) were computationally identified. linsitinib demonstrated the most favorable in silico binding affinity in molecular docking simulations. This finding has not yet been validated experimentally and requires future in vitro and in vivo confirmation. Under hyperglycemic stress, HASMCs exhibited reduced proliferation, elevated apoptosis and senescence, alongside increased expression of p16, p21, OPN, and OC. Augmentation of MMP14 expression and suppression of FOS promoted cell proliferation while mitigating hyperglycemia-induced apoptosis and senescence. Cell cycle analysis revealed that high glucose induced G0/G1 phase arrest, which was relieved by MMP14 overexpression or FOS knockdown, and further exacerbated by MMP14 knockdown or FOS overexpression. All functional findings were consistently recapitulated in HRASMCs, confirming the conserved regulatory roles of MMP14 and FOS across VSMC subtypes.

CONCLUSION:

MMP14 and FOS function as crucial modulators of VSMC senescence in DKD, presenting diagnostic and therapeutic opportunities. The characterized regulatory circuits and identified pharmaceutical agents establish a foundation for precision interventions in DKD management.

01 Aug 2026·COMPUTATIONAL BIOLOGY AND CHEMISTRY

Network pharmacology and in silico docking-based prediction of molecular targets of Pterospermum acerifolium in primary breast cancer and metastases to bones

Article

Author: Godbole, Mukul S ; Naik, Amruta ; Kharade, Shutija ; Datt, Manish

Breast cancer is known to metastasize to distinct organs, including bones. Dysregulation of cellular receptors-particularly estrogen and growth factor receptors-drives tumor progression, therapy resistance, and metastasis. Natural bioactive compounds have potential to modulate multiple molecular targets, with minimal side effects. Here, we applied a network pharmacology and molecular docking approach to investigate the therapeutic potential of Pterospermum acerifolium in primary breast cancer and bone metastasis. While Pterospermum acerifolium possesses pharmacological properties-antioxidant and anti-inflammatory effects-its potential impacts on breast cancer metastasis remain largely uninvestigated. Based on literature and pharmacokinetic profiles of Pterospermum acerifolium, we selected three compounds viz. kaempferol, luteolin and β-sitosterol. We identified predicted genomic targets of these compounds from databases, and compared their lists of genes with those associated with breast cancer and its metastasis to bones. Functional enrichment analyses of the overlapping genes suggested association of cellular pathways central to tumor progression and bone metastasis, including PI3K-Akt, MAPK, VEGF and estrogen signaling. Network construction further identified key receptor-based targets-ERα, ERβ, IGF1R and VEGFR2-as hub-genes based on degree of centrality and connectivity within the protein-protein interaction network. Further, we performed molecular docking analyses to evaluate compound-receptor binding affinities; analyses revealed strong binding affinities, particularly with β-sitosterol, suggesting the multi-target therapeutic action. Interestingly, the molecular docking analyses indicated β-sitosterol to have stronger affinity to ERα, ERβ, IGF1R and VEGFR2 than that of their known inhibitors (tamoxifen, diarylpropionitrile, linsitinib and sorafenib, respectively). The analyses also identified key amino acids involved in the interactions of bioactive compounds with binding pocket of the four native protein structures, some of which were similar to those involved in interactions with the known inhibitors. Finally, molecular dynamics simulations analyses confirmed strong molecular interactions of β-sitosterol with VEGFR2 and ERβ. Taken together, the findings highlight potential of phytoconstituents of Pterospermum acerifolium, especially β-sitosterol, kaempferol and luteolin, for clinical management of breast cancer and its metastasis to the bone.

01 May 2026·Respiratory Investigation

Insulin-like growth factor 1 by lung fibroblasts from patients with idiopathic pulmonary fibrosis contributes to the development of fibrosis

Article

Author: Saito, Shoichiro ; Kumamoto, Makiko ; Muro, Shigeo ; Ito, Toshihiro ; Kitabatake, Masahiro ; Hontsu, Shigeto ; Furukawa, Ryutaro ; Hara, Atsushi ; Ouji-Sageshima, Noriko ; Akiyama, Yuzu ; Sawabata, Noriyoshi ; Kasamatsu-Nishimura, Tomoko ; Kawaguchi, Takeshi ; Hamaji, Masatsugu

BACKGROUND:

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive form of interstitial pneumonia with a poor prognosis. IPF is mainly caused by the excessive synthesis and accumulation of the extracellular matrix produced by myofibroblasts. However, the mechanisms underlying the disease progression of IPF have not been fully elucidated.

METHODS:

To identify fibrosis-associated genes while minimizing genetic heterogeneity, pulmonary fibroblasts were derived from paired non-fibrotic (NF) and fibrotic (F) areas of lungs from patients with IPF, and gene expression profiles were compared. Functional analyses of fibroblasts were performed by stimulation with transforming growth factor-β (TGF-β) and/or insulin-like growth factor 1 (IGF-1), or by the pharmacological inhibition of TGF-β and IGF-1 receptor (IGF-1R) signaling.

RESULTS:

IGF-1 expression was significantly higher in lung F areas than in the NF areas of IPF lungs. IGF-1 expression was positively correlated with fibrotic marker genes. Stimulation of IPF lung fibroblasts with TGF-β induced time-dependent increases in IGF-1 and α-smooth muscle actin expression, whereas the inhibition of TGF-β signaling suppressed IGF-1 expression. Although IGF-1 itself did not enhance fibrotic marker expression, co-stimulation with TGF-β augmented TGF-β-driven profibrotic gene expression. Furthermore, the inhibition of IGF-1R signaling with OSI-906, a selective IGF-1R inhibitor, attenuated fibrotic marker expression under TGF-β alone and TGF-β plus IGF-1 stimulation conditions.

CONCLUSIONS:

These results suggest that IGF-1 amplifies TGF-β-driven profibrotic responses and may represent a potential therapeutic target for IPF.

News (Medical) associated with Linsitinib

05 May 2026

·allsci.com

Viridian’s elegrobart meets primary endpoint in Phase III chronic thyroid eye disease trial

Viridian Therapeutics (Nasdaq: VRDN) reported that elegrobart (VRDN-003) met its primary endpoint in the Phase III REVEAL-2 trial in chronic thyroid eye disease (TED), with proptosis responder rates of 50% and 54% for the every-four-week and every-eight-week dosing arms, respectively, compared with 15% for placebo — results the company described as highly statistically significant at p \< 0.0001 for both arms. The REVEAL-2 trial is a randomized, placebo-controlled Phase III study that enrolled 204 patients with chronic thyroid eye disease, allocated 1:1:1 across elegrobart every four weeks (Q4W), elegrobart every eight weeks (Q8W), and placebo, with a primary analysis at week 24. Elegrobart is a subcutaneously delivered, half-life-extended monoclonal antibody targeting the insulin-like growth factor-1 receptor (IGF-1R). The proptosis responder rate served as the FDA primary endpoint, while an overall responder rate — defined as combined proptosis and Clinical Activity Score response — served as the EMA primary endpoint. Both were met with high statistical significance across both active arms. Mean proptosis reduction from baseline was -1.9 mm in the Q4W arm and -2.1 mm in the Q8W arm, versus -0.5 mm for placebo, again at p \< 0.0001. On diplopia, the Q4W arm achieved a 61% responder rate versus 38% for placebo (p \= 0.0118), with complete diplopia resolution in 44% of Q4W patients versus 25% on placebo (p \= 0.0295). The Q8W arm showed a 55% diplopia responder rate (p \= 0.0419), though diplopia complete resolution in that arm did not reach statistical significance at p \= 0.1304. Efficacy was reported as consistent regardless of baseline Clinical Activity Score. A total 91% of elegrobart-treated patients completed the full treatment course, and no treatment-related serious adverse events were observed. Rates of hearing impairment — a class effect associated with IGF-1R inhibition — were low, at placebo-adjusted rates of 4.1% and 8.8% in the Q4W and Q8W arms, respectively. The chronic TED population is distinct from the active disease setting. Patients with chronic TED typically have lower inflammatory activity as measured by the Clinical Activity Score but can carry persistent proptosis and diplopia for years or decades. Treatment options in this population have historically been limited. The only approved IGF-1R inhibitor for TED is teprotumumab, an intravenous agent that established the mechanistic validity of IGF-1R blockade in this disease. Elegrobart’s subcutaneous delivery and extended half-life are designed to enable less frequent dosing and home administration via autoinjector, which Viridian argues could expand uptake among patients who have not pursued intravenous infusion-based therapy. Cross-trial comparisons are limited by differences in patient populations, endpoints, and trial design, so direct efficacy comparisons between elegrobart and teprotumumab cannot be drawn from available data. REVEAL-2 is the second positive pivotal Phase III readout for elegrobart, following REVEAL-1, which evaluated the drug in active TED. Viridian has also reported positive Phase III data for its intravenous IGF-1R antibody veligrotug from the THRIVE and THRIVE-2 trials in active and chronic TED, respectively. Veligrotug has received Breakthrough Therapy Designation from the FDA and is currently under Priority Review with a PDUFA target action date of June 30, 2026. The company intends to use the commercial and medical affairs infrastructure built for a potential veligrotug launch to support a subsequent elegrobart launch, if approved, with what it describes as limited incremental investment. Viridian said it remains on track to submit a Biologics License Application to the FDA for elegrobart in the first quarter of 2027. If that submission proceeds and approval follows, elegrobart would be positioned as the first subcutaneous autoinjector treatment for TED, spanning both active and chronic disease based on two pivotal trials. The competitive landscape in TED is becoming more active: lonigutamab, another subcutaneous anti-IGF-1R antibody in development, has reported Phase I/II data, though it remains earlier-stage than elegrobart. Oral IGF-1R inhibitors, including linsitinib from Sling Therapeutics, have also entered late-stage TED development, potentially broadening the routes of administration available to patients and prescribers. The REVEAL-2 dataset adds to a body of evidence suggesting that IGF-1R inhibition retains meaningful activity in the chronic phase of TED, where spontaneous improvement is less predictable and the inflammatory driver that characterizes active disease is less prominent. The magnitude of proptosis reduction observed — approximately 2 mm on average — is in a range that has been considered clinically relevant in prior TED trials, though formal responder thresholds and the relationship between millimeter-scale changes and patient-reported outcomes remain subjects of ongoing discussion in the field. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/ Your email address will not be published. Required fields are marked * Comment * Name * Email * Website

06 Apr 2026

·www.fiercepharma.com

Amgen scores with trial of on-body injected version of Tepezza in thyroid eye disease

A phase 3 trial of patients with thyroid eye disease has shown that subcutaneous injection of Tepezza by way of an on-body injector can provide comparable efficacy to its current route of administration, which includes eight infusions over 24 weeks. Since acquiring rare disease specialist Horizon Therapeutics in 2023 for $27.8 billion, Amgen has had difficulty boosting sales for the top product gained in the buyout, thyroid eye disease (TED) treatment Tepezza.But with a new, patient-friendly route of administration, the California biotech may have found a way to increase demand for Tepezza, which is the lone drug on the market for the inflammatory, bulging-eye condition.A phase 3 trial of patients with moderate-to-severe TED has shown that subcutaneous injection of Tepezza by way of an on-body injector (OBI) can provide comparable performance to its current route of administration, which includes eight intravenous (IV) infusions, three weeks apart, each lasting between 60 and 90 minutes.The trial met its primary endpoint, as Tepezza OBI demonstrated a statistically significant and clinically meaningful proptosis response rate of 77% compared to a 20% figure for those on placebo, according to a Monday press release from Amgen. Patients were considered responsive if they achieved a 2-mm or greater reduction from baseline in proptosis (eye protrusion) without deterioration after 24 weeks.As a key secondary endpoint, Tepezza OBI provided an average proptosis reduction of 3.17-mm at week 24, compared to an average reduction of 0.80-mm in the control arm.“These results extend and support the best-in-class efficacy of Tepezza for people living with thyroid eye disease, now with subcutaneous administration delivering IV-level efficacy,” Amgen’s R&D chief, Jay Bradner, said in the release. “With a well-understood mechanism and established impact in the clinic, we can evolve how the medicine is delivered to potentially reach even more patients through a more convenient subcutaneous option.”Amgen did not reveal its regulatory plan in its release. A spokesperson said that the company will submit the results to authorities but that it is “too early to comment on approval timing as that depends on a number of regulatory factors.” Horizon’s 2020 FDA approval for Tepezza IV was backed by results from a phase 3 trial, which showed an 83% response rate—again defined by a 2-mm proptosis reduction at 24 weeks—compared to a 10% reduction in the placebo arm. In its second full year on the market in 2022, Tepezza’s sales peaked at $1.96 billion. Since then, sales have been stagnant. Last year, Amgen reported its sales at $1.90 billion.Competition may be coming for Tepezza. Massachusetts-based Viridian Therapeutics faces a June 30 FDA decision date for its TED candidate veligrotug, which is infused five times over a 12-week period.Last week, Viridian also scored a phase 3 win for its injected TED prospect elegrobart, but with results that did not impress investors. The study’s responder rate was 54% for the drug candidate compared to 18% for the placebo group. Elegrobart provided a 2.33-mm mean reduction at 24 weeks compared with 0.81-mm for placebo."We believe Viridian’s veligrotug and elegrobart have the potential to capture significant share in the TED market," William Blair analyst Lachlan Hanbury-Brown wrote in a note to investors. "We believe veligrotug offers a competitive profile relative to current standard-of-care Tepezza, and believe the more convenient dosing and diplopia benefits in chronic TED should translate into a meaningful commercial opportunity."Last year, Michigan-based Sling Therapeutics shared results from a phase 2b/3 TED trial of its oral challenger, former Astellas asset linsitinib, though the data suggested that the treatment doesn’t measure up to the efficacy of Tepezza, providing a 52% responder rate. Amgen added on Monday that it has completed a phase 3b/4 trial of Tepezza IV to fulfill an FDA post-marketing requirement. The trial’s mission was to assess the tolerability and efficacy of three treatment durations (four, eight and 16 infusions) and assess the need for retreatment.The company said that the observed risk profile was "consistent" with the known profile of the current administration regimen and that those results will be will submitted to regulators and presented at an upcoming medical conference.Editor's note: Commentary from William Blair analyst Lachlan Hanbury-Brown was added to this story after its initial publication.

Phase 3Clinical ResultDrug Approval

06 Apr 2026

·allsci.com

Amgen’s subcutaneous Tepezza meets primary endpoint in Phase III thyroid eye disease trial

Amgen (NASDAQ: AMGN) reported that a Phase III trial of subcutaneous teprotumumab-trbw (Tepezza) delivered via an on-body injector met its primary endpoint in moderate-to-severe active thyroid eye disease, with 76.7% of patients achieving a proptosis response at week 24 versus 19.6% on placebo — a result that positions the reformulation as a potential administration alternative to the already-approved intravenous version. Trial specifics The Phase III TEPEZZA OBI trial is a randomized, double-masked, placebo-controlled, multicenter study enrolling adults with moderate-to-severe active thyroid eye disease, delivering teprotumumab or placebo via on-body injector every 2 weeks for 12 injections over 24 weeks. At week 24, the proptosis responder rate — defined as a ≥2 mm reduction in the study eye without ≥2 mm deterioration in the fellow eye — was 76.7% for the subcutaneous arm versus 19.6% for placebo (p<0.0001). The key secondary endpoint, mean proptosis reduction, was −3.17 mm versus −0.80 mm for placebo (p<0.0001). Additional secondary endpoints, including diplopia response rate, Clinical Activity Score of 0 or 1, and the Graves' Ophthalmopathy Quality of Life appearance subscale, also met statistical significance. The GO-QoL visual functioning subscale showed a numerical trend favoring treatment but did not reach statistical significance. The safety profile was consistent with that of intravenous Tepezza. Mild-to-moderate injection site reactions occurred in some patients but did not lead to treatment interruption or discontinuation. The most common adverse events occurring in ≥10% of patients were muscle spasms, tinnitus, weight decrease, ear discomfort, nausea, and diarrhea — a pattern familiar from the IV formulation’s established label. The development context Teprotumumab is a fully human monoclonal antibody that blocks insulin-like growth factor-1 receptor (IGF-1R) signaling on orbital fibroblasts, the pathway through which autoantibodies drive the inflammation, glycosaminoglycan deposition, and proptosis characteristic of thyroid eye disease. The IV formulation received FDA approval in 2020 as the first and only approved medicine for TED and has since been used in more than 25,000 patients. The subcutaneous program does not alter the molecule or its target; it repackages the same active ingredient into a format that could, if approved, eliminate the requirement for infusion center visits. That distinction matters commercially. The IV regimen involves eight infusions over 24 weeks, with infusion times of about 90 minutes for the first two doses and as little as 60 minutes thereafter if tolerated. For a condition that already imposes substantial functional burden — proptosis, diplopia, and periorbital pain can significantly limit daily activity — the added logistical demand of repeated infusion visits is a recognized friction point. A subcutaneous option delivered via an on-body injector could extend access to patients in geographies without infusion infrastructure and reduce the overall treatment burden, though whether payers and prescribers will view the convenience premium as justifying any additional cost differential remains to be seen. The competitive context for this data is worth examining. Immunovant’s batoclimab, an FcRn inhibitor that reduces pathogenic IgG antibodies rather than directly targeting IGF-1R, failed to meet the primary proptosis endpoint in two Phase III trials in TED. Sling Therapeutics’ linsitinib, an oral small-molecule inhibitor of IGF-1R and the insulin receptor, has reported positive topline results from its Phase II/III LIDS study. Cross-trial comparisons are limited by differences in patient populations, endpoint definitions, and trial designs, but the landscape suggests that direct IGF-1R blockade via teprotumumab retains the most mature efficacy dataset in this indication, and the subcutaneous program extends that dataset without introducing mechanistic uncertainty. Amgen noted separately that a Phase IIIb/IV post-marketing requirement study of intravenous Tepezza — evaluating three treatment durations of 4, 8, and 16 infusions and the need for retreatment — has been completed. That study was descriptive in nature, and its safety observations were consistent with the known IV profile. Data from both studies will be submitted to regulatory authorities and presented at an upcoming medical congress; no regulatory submission timeline for the subcutaneous formulation was disclosed in the topline release. Leave a Reply Cancel reply Your email address will not be published. Required fields are marked * Comment * Name * Email * Website

Clinical ResultPhase 3Drug Approval

100 Deals associated with Linsitinib

External Link

KEGG	Wiki	ATC	Drug Bank
D09925	Linsitinib	-	DB06075

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Graves Ophthalmopathy	Phase 3	Canada	Sling Therapeutics, Inc.	01 Jul 2022
Graves Ophthalmopathy	Phase 3	Italy	Sling Therapeutics, Inc.	01 Jul 2022
Graves Ophthalmopathy	Phase 3	Spain	Sling Therapeutics, Inc.	01 Jul 2022
Graves Ophthalmopathy	Phase 3	United Kingdom	Sling Therapeutics, Inc.	01 Jul 2022
Hashimoto Disease	Phase 3	United States	Sling Therapeutics, Inc.	01 Jul 2022
Hashimoto Disease	Phase 3	Canada	Sling Therapeutics, Inc.	01 Jul 2022
Hashimoto Disease	Phase 3	Italy	Sling Therapeutics, Inc.	01 Jul 2022
Hashimoto Disease	Phase 3	Spain	Sling Therapeutics, Inc.	01 Jul 2022
Hashimoto Disease	Phase 3	United Kingdom	Sling Therapeutics, Inc.	01 Jul 2022
Adrenocortical Carcinoma	Phase 3	United States	Astellas Pharma, Inc.	01 Dec 2009

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01560260 (SARC, Pubmed \| Clin Cancer Res) Manual	Phase 2	Gastrointestinal Stromal Tumors	20	Linsitinib	gqnntsckrz(mwakcwkocw) = mmjqanfbcv ozjzytyvvc (qqpnjjeywm ) View more	Positive	15 Apr 2020
NCT02546544 (LINES, CTgov)	Phase 2	Recurrent Ewing Sarcoma \| Refractory Ewing Sarcoma	16	Linsitinib	nnzzvwglkf(hefsjjmhpo) = fjldscreyl mevlpbwzzn (zfkepplsok, mdrzsattsk - uccjmsoprq) View more	-	03 Jun 2019
NCT01672736 (CTgov)	Phase 1/2	Relapse multiple myeloma	19	Dexamethasone+Velcade+ASP7487	zzghwkflvv = qdwsgnppvt tvlcekqpic (qbuptptkxt, mddacgwkja - nqfsokpkul) View more	-	13 Sep 2018
NCT01186861 (Pubmed \| Med J Aust) Manual	Phase 2	Non-Small Cell Lung Cancer Maintenance	205	erlotinib+linsitinib	wyaqommotj(jsufewrpdx): P-Value = 0.601 View more	Negative	05 Sep 2017
				erlotinib+Placebo
NCT01560260 (SARC, CTgov)	Phase 2	Paraganglioma \| Chondrosarcoma \| Gastrointestinal Stromal Tumors ... View more	20	Pharmacological Study+Linsitinib	roapwneysr = jkfvswdhbk bnjsvcmanz (vyjcaxktgz, fwwjnihcqe - mjfxeubhyo) View more	-	19 Jan 2017
NCT01221077 (Pubmed \| Clin Lung Cancer) Manual	Phase 2	Non-Small Cell Lung Cancer	88	erlotinib+Linsitinib	qktndmcxks(rpmcvlltyj) = rhepbmyqfz fwpyjmivgo (swdcgntvef ) View more	Negative	01 Jan 2017
				erlotinib+Placebo	qktndmcxks(rpmcvlltyj) = vsybjqbkev fwpyjmivgo (swdcgntvef ) View more
NCT01533181 (Pubmed \| Oncologist) Manual	Phase 2	Recurrent Lung Small Cell Carcinoma	44	Topotecan Hydrochloride	cwlyhpbxow(zdksejjzqg) = givltdcpda vkmnqhbjfv (cjixjrercd, 1.5 - 3.6) View more	Negative	01 Oct 2016
				Linsitinib	cwlyhpbxow(zdksejjzqg) = dfjcnykgzm vkmnqhbjfv (cjixjrercd, 1.1 - 1.4) View more
NCT01533181 (CTgov)	Phase 2	Recurrent Lung Small Cell Carcinoma	44	Topotecan (Arm A: Topotecan)	njkbmivzrh(ubkvwxlstc) = btkemuwxmn aqnfbzanmm (mhvbcaegyp, kerjjvppfc - beiveettdv) View more	-	14 Jan 2016
				OS-906 (Arm B: OS-906)	njkbmivzrh(ubkvwxlstc) = sauzmjrnyj aqnfbzanmm (mhvbcaegyp, yaguqrmikp - bvasnananu) View more
NCT00924989 (Pubmed \| Lancet Oncol) Manual	Phase 3	Adrenocortical Carcinoma	139	Linsitinib	awevsmhysd(ogxnihojgi) = opopjkizwj auiuwghypd (dnygwfrmam )	Negative	01 Apr 2015
				Placebo	awevsmhysd(ogxnihojgi) = iougpsipzm auiuwghypd (dnygwfrmam ) View more
NCT01533246 (CTgov)	Phase 2	Recurrent Prostate Carcinoma \| Metastatic castration-resistant prostate cancer \| Adenocarcinoma of prostate	17	laboratory biomarker analysis+linsitinib	fbwwzphrtv = yivooqfyys nzrrhvgvga (icuvwzpyep, oeohmdnhcg - ztfxcvlnda) View more	-	13 Mar 2015

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis